CompletedNot Applicable

Oral Bifidobacterium Longum for Skin Barrier Dysfunction in Obesity

China140 participantsStarted 2025-09-09

Plain-language summary

This clinical trial aims to evaluate the safety and efficacy of oral Bifidobacterium longum supplementation for treating obesity-induced skin barrier impairment in individuals aged 18-40 with BMI ≥30, compared to healthy controls. The study focuses on the following questions: Can oral Bifidobacterium supplementation reduce skin barrier damage (measured by transepidermal water loss/TEWL) in obese participants? Does modulation of gut microbiota with Bifidobacterium longum impact skin barrier function and systemic inflammation? Researchers will compare outcomes across two groups: * Intervention Group (Obese): Oral Bifidobacterium longum capsules * Placebo Control Group (Obese): Oral inactive Bifidobacterium longum (heat-killed) Participant Procedures: Take daily oral capsules (Bifidobacterium longum or inactive strain) for 4 weeks Undergo non-invasive skin testing (TEWL measurements) at baseline and study completion Provide blood, stool, and skin swab samples for inflammation and microbiome analyses Complete weekly check-ins to report adverse effects (e.g., gastrointestinal discomfort, skin irritation)

Who can participate

Age range

18 Years – 40 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria : * 1\. Meets 2020 WHO BMI classification: * a. Normal weight (18.5-24.9 kg/m²) * b. Overweight (25-29.9 kg/m²) * c. Obesity (≥30 kg/m²) * 2\. Presence of skin barrier impairment (e.g., dryness, erythema, desquamation, or itching) * 3\. Age 18-40 years * 4\. Generally good health (no active systemic diseases) * 5\. Able and willing to provide written informed consent * 6\. No use of oral/topical medications or probiotics within 6 months prior * 7\. No active skin disease or traumatic skin lesions Exclusion Criteria : * 1\. Known allergy or hypersensitivity to probiotics, placebo, or investigational product * 2\. Active skin disease (e.g., psoriasis, eczema, infection) requiring treatment * 3\. Severe medical conditions: * a. Cardiopulmonary disease (NYHA class III/IV) * b. Uncontrolled diabetes (HbA1c \>9%) * c. Autoimmune disorders * 4\. Pregnant or breastfeeding women * 5\. Any condition that may interfere with protocol compliance (per investigator judgement), including: * a. Inability to understand study procedures * b. History of poor clinical trial adherence * 6\. Concurrent participation in other interventional trials

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Mean change in transepidermal water loss (TEWL, g/h/m²) on the volar forearm from baseline to 1 month after intervention, measured by Tewameter

Timeframe: Baseline through 1 month after intervention

Trial details

NCT IDNCT07184905

SponsorShenzhen People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-27

View on ClinicalTrials.gov More Skin Barrier to Water Loss trials